Form 4: CVS Health Executive Reports Stock Transactions

Steven H. Nelson, EVP and President of Aetna at CVS Health, reported transactions involving restricted stock units and common stock.

Summary

• Steven H. Nelson, Executive Vice President and President of Aetna, reported a transaction on March 31, 2026, involving the acquisition of 22,277 restricted stock units at a price of $71.82 per share.
• On April 1, 2026, Mr. Nelson disposed of 2,432 shares of common stock for $72.49 per share, which were surrendered to cover withholding taxes upon the vesting and settlement of restricted stock units.
• Additionally, a stock option was granted on March 31, 2026, with an exercise price of $71.82, covering 143,712 shares of common stock. This option becomes exercisable in three equal annual installments starting March 31, 2027, and expires on March 31, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and compensation-related events rather than significant strategic or financial performance indicators.

Positives

• Acquisition of restricted stock units indicates potential long-term incentive and alignment with company performance.
• Grant of stock options suggests management's continued commitment and potential for future gains tied to stock appreciation.

Negatives

• Surrender of shares to cover withholding taxes on vested restricted stock units represents a reduction in the net shares received by the executive.

Future Outlook

The stock option granted on March 31, 2026, becomes exercisable in three equal annual installments starting March 31, 2027, indicating a phased approach to executive equity realization tied to future performance and vesting periods.

Industry Context

StockSavvy.ai notes that the transactions reported on Form 4 are standard for executive compensation and incentive programs within the healthcare and pharmacy retail industry, reflecting typical award structures for senior leadership.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not immediately indicate a change in beneficial ownership that would significantly impact share price, though the vesting and exercise of options could lead to future share dilution.

Next Steps

• Vesting of restricted stock units in three equal installments commencing March 31, 2027.
• Exercisability of stock options in three equal annual installments commencing March 31, 2027.

Key Dates

Keywords

CVS Health, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Securities Transaction